|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adam Stops, PhD, says the key to the success of any drug delivery device are factors such as proven technology, low development costs, fast time-to-market, and a strong intellectual property (IP) position for the pharma company, and against this background, platform drug delivery devices have become more important than ever.
|
|
|
Chris Preti, President of Jubilant HollisterStier, discusses how the CMO is handling increased demand for sterile fill finish and how expertise makes a difference to customer relationships and finished product quality.
|
|
|
Martin Gonzalez, PhD, details current trends in sterile injectable formulations and delivery devices and highlights the challenges pharma and its CDMO partners are facing bringing emerging parenteral breakthroughs to patients.
|
|
|
After a brief fall in 2022 to a score of 6.5 – the first decline since its inception in 2018 – the index has surged to a record score of 7.4. This sudden recovery in scores over a little more than 8 months bodes extremely well for device and packaging manufacturers in the year ahead, suggesting a strong global recovery in industry outlook and confidence.
|
|
|
|
|
|
|
|
|

With more than 70 years’ experience in medical devices, Owen Mumford Pharmaceutical Services is a division of Owen Mumford, with the Head Office located in Woodstock, UK. Our global presence extends from manufacturing facilities in the UK and Malaysia to subsidiaries in the US, Germany, and France. Owen Mumford Pharmaceutical Services specialises in the design, development, and manufacture of injectable drug delivery systems for the pharmaceutical, biotech, and generics industries. Our trusted devices are used daily in the delivery of various medications for a multitude of conditions across the globe. Click here for more.
|
|
|
|
|
|
 |
|
Leading integrated drug discovery partner, Sygnature Discovery, recently announced its acquisition of one of North America’s largest discovery Contract Research Organizations, Canada-based….
|
|
 |
|
ProQR Therapeutics N.V. and Laboratoires Théa recently announced an agreement in which ProQR will divest its late-stage ophthalmic assets, sepofarsen and….
|
|
 |
|
On World Lung Cancer Day, Ocean Biomedical, Inc. is sharing details of its multi-pronged Lung Cancer Program built on novel immunotherapy discoveries by Scientific Co-founder Dr. Jack A. Elias. He and his team have revealed that Chitinase 3-like-1 (CHi3L1) is a master regulator that inhibits….
|
|
 |
|
In response to the growing legislation around per- and polyfluoroalkyl substances (PFAS), Mitsubishi Gas Chemical (MGC) has launched the first future-proof, eco-friendly packaging solution for the industry using a cleaner chemistry within record-breaking turnaround…..
|
|
|
|
|
|
|
|
 |
|
By: Jeffrey Tremain and Ania VanDyke, AbbVie Contract Manufacturing
Regulatory authorities now consider ophthalmic formulations designed for administration as eye drops to be drug-device combination products.The regulatory compliance requirements for such combination products are much more complex than those for …
|
|
 |
|
Active pharmaceutical ingredients (APIs) can exist in multiple crystal forms, known as polymorphs, that are chemically identical. Polymorphs of an API can appear over the course of development and lead to deviations across batches affecting stability, tableting properties, flowability, solubility, …
|
|
 |
|
Owing its convenience, oral administration is patients’ preferred route of delivery for therapeutic molecules. However, most New Chemical Entities (NCE) exhibit physico-chemical properties limiting their absorption in the gastro-intestinal (GI) tract. Indeed, according to Pharmacircle data from March 2022, almost …
|
|
 |
|
Long acting injectable (LAI) formulations have been the subject of continued interest in the recent past due, in part, to their longer systemic circulation requiring less frequent dosing of drugs. Less frequent administration, as illustrated in Figure 1, make LAIs …
|
|
 |
|
What’s In This Whitepaper?
Long-acting products, such as Long-Acting Injectables (LAIs) and implantables, have gained significant traction in recent years, revolutionizing patient treatment and medication adherence. By reducing the number of doses required, long-acting products improve patient compliance and eliminate …
|
|
|
|
|
Upcoming eNewsletter Features:
August 16 – Lyophilization Manufacturing
August 23 – Excipients
|
|
|
|
|
|
|
|